VALENCIA, Calif., March 28 /PRNewswire-FirstCall/ -- MannKind Corporation , focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference to be held April 4-5, 2006 at the Millennium Broadway Hotel in New York City.
Management is scheduled to speak on Wednesday, April 5, 2006 at 10:30 a.m. Eastern Time (7:30 a.m. PT). Management will provide an update on the Company.
Interested parties can access a link to the live web cast of the presentation in the Investor Relations section of the Company’s website at www.mannkindcorp.com. A replay of the presentation will be available for 14 days.
About MannKind Corporation
MannKind Corporation focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead investigational product candidate, the Technosphere(R) Insulin System, is currently in phase 3 clinical trials in the U.S. and Europe to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit www.mannkindcorp.com.
MannKind Corporation
CONTACT: Dick Anderson, Chief Financial Officer of MannKind Corporation,+1-661-775-5302, danderson@mannkindcorp.com; or Investor Relations, JulieHuang of Financial Dynamics, +1-212-850-5628, mnkd@fd-us.com, for MannKindCorporation
Web site: http://www.mannkindcorp.com/
